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Immunotherapy of cancer must be effective in the pre-established disease; i.e., in the therapeutic rather than
prophylactic setting. Here, we review novel immunotherapeutic approaches for targeting established can-
cers. In addition to novel checkpoint-blocking antibodies, recent insight into innate immune sensors may
further improve cancer immunotherapy protocols and help to overcome the limitations of conventional
therapeutic immunization strategies. Specifically, the local induction of IL-12 and IFNa turns the immunosup-
pressive tumor microenvironment into an immunosupportive tissue, which is attained, for example, by local
Toll-like receptor or RIG-I-like receptor triggering. Notably, the latter are endogenously expressed in all tumor
cells and have the advantage of turning tumors into tumor vaccines by inducing apoptosis and improving
antigen presentation. Thus, immunostimulatory agents embody strong promise as a part of combinatorial
cancer immunotherapies.A major hurdle for therapeutic tumor immunotherapy is that the
majority of tumor cells and their associated antigens are located
in an immunosuppressive tumor environment. Despite the fact
that large populations of tumor-reactive T cells can be raised in
patients by active immunization or adoptive T cell transfer,
T cells cannot fully realize their tumoricidal potential inside the
tumor tissue. Therefore, an abundance of tumor antigen-specific
T cells do not readily translate to tumor destruction (Mocellin
et al., 2004).
Combinatorial immunoregimens are needed to augment the
immune response at all levels. An important component will be
the conversion of the tumor microenvironment into an immuno-
supportive tissue, thereby enabling the employment of tumor
antigens in an immunostimulatory context. Immunogenic con-
version of the tumor microenvironment can be achieved by
intratumoral administration of appropriate immunostimulatory
compounds. Such compounds include agents that induce IL-
12 or type I IFN rather than simply inducing tumor inflammation.
Unlike the classical type I IFN-inducing compounds targeting
Toll-like receptors (TLRs) in immune cells, innate immune
sensors of the RIG-I family are expressed in the cytoplasm of
all cells, including tumor cells, and are not under the control of
extracellular immunosuppressive cytokines such as IL-10 or
TGF-b. The activation of RIG-I stimulates tumor cells to produce
type I IFN and, ultimately, induces tumor cell apoptosis and
antigen liberation. The resulting immunosupportive tumor
microenvironment can be combined with therapeutic tumor
vaccination strategies and checkpoint blockade inhibitors. In
this review, we detail the rationale behind such combinatorial
approaches.
Jus Ad Bellum
The infiltration of tumors with leukocytes, first observed by
Rudolf Virchow in the 1800s, indicates that the immune system
is engaged with the malignant tissue. Nevertheless, tumors
progress while immunity fails. In an endeavor to induce active
immune-mediated clearance of established tumors, manydifferent strategies of immunotherapy have been developed
over the past decades. Some of them have shown considerable
activity in clinical trials, but many have turned out to be of limited
therapeutic value. Strictly speaking, cancer immunotherapy has
not met the expectations set forth since the pioneering work on
Coley’s toxins in the 1880s (Coley, 1891; Fehleisen, 1883).
Now, the reasons are gradually being unveiled. Considerable
progress has been made in the understanding of the immune
sensory system and tumor plasticity. This has provided an array
of new targets and tools, and it is now very clear that the proper
immune sensory input results in immune effector cells targeting
and destroying autologous tumor cells. In addition, new antibody
therapies were developed that release these immune effector
cells from their natural restraints (anti-CTLA4 and anti-PD1).
Now, multileveled immunotherapies are within reach, and it
comes down to the right armament and tactics, given that the
immune system appears to be quite capable of clearing tumors.
Tumor Plasticity and Immunity
A large body of evidence supports the concept that the immune
system actively shapes tumor immunogenicity during tumori-
genesis (Dunn et al., 2002). The immune system can protect
from carcinogen-induced sarcoma and spontaneous epithelial
carcinoma in the course of immunosurveillance (Shankaran
et al., 2001). Immune pressure during tumorigenesis canmediate
the selective outgrowth of tumor cell clones lacking immuno-
genic antigens (Matsushita et al., 2012) or exhibiting decreased
sensitivity to immune attack (DuPage et al., 2012), a process
called immunoediting. Immunoediting is facilitated by the high
clonal heterogeneity present in established tumors and is multi-
plied by genetic instability and proliferative capacity. Thereby,
immunoediting is the result of clonal tumor cell evolution in the
face of selective immune- and therapy-induced pressures, a
phenomenon that is discussed below.
Apart from immunoediting acting on a clonal basis, individual
tumor cells can also respond with evasive plasticity. For ex-
ample, T-cell-induced inflammation is not necessarily beneficialImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 27
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autochtonous murine melanoma, Landsberg et al. (2012) closely
recapitulated the clinical adoptive cell transfer (ACT) protocol
used as melanoma immunotherapy regimen. Although this treat-
ment was highly effective in initially eradicating the melanomas,
after approximately two months, tumors recurred aggressively
in a subgroup of mice (Kohlmeyer et al., 2009; Landsberg
et al., 2012; 2010). Relapsed tumors showed a dedifferentiated
mesenchymal-like phenotype with loss of gp100 and melan-A
antigens and 23 other pigmentation genes along with an upregu-
lated nerve growth factor expression (CD271). Strikingly, isola-
tion and retransplantation of these dedifferentiated melanomas
into naive animals resulted in a tumor phenotype that was again
susceptible to the same ACT protocol. However, as in the first
round, the tumors gained resistance to ACT treatment. This
reversible dedifferentiation was mediated by TNFa produced
by tumor-infiltrating immune cells. Selective proliferation and
selection of dedifferentiated subclones was excluded in the
study design. These results highlight the plasticity of individual
melanoma cells in functionally evading immunotherapy-induced
T cell attack with no need for genetic adaptation. Interestingly,
the TNFa-induced resistance to T cell recognition was confined
to the melanocyte differentiation antigens and did not affect
T cell recognition of the mutated CDK4 protein. Besides broad-
ening the immunoediting principle, and thereby adding flexibility
to the clonal evolution theory (Greaves and Maley, 2012; Nowell,
1976), these findings call for a broader therapeutic antigen
scope and emphasize the careful coordination of inflammatory
responses within the tumor ecosystem.
Tumor Therapy Resistance and Clonal Revolution
Enduring tumor inflammation facilitates progressive tumor
growth, a highly complex polyclonal process. Nearly four de-
cades ago, Nowell (1976) put forward the theory of tumorigen-
esis as an evolutionary process. More recent reviews byGreaves
and Maley (2012) and Merlo et al. (2006) address the current
understanding of the subject and emphasize the fact that each
therapy introduces a new selective pressure on the clonal evolu-
tion within the tumor. Thereby, basically all therapies will induce
resistance by mediating the natural selection of resistant tumor
cells. The clonal evolution theory is supported by the observation
that intratumoral mutational heterogeneity, the prerequisite for
such evolution, is extensive (Gerlinger et al., 2012). Gene expres-
sion profiles of good and bad prognosis were found dispersed
over a single tumor mass, and multiple distinct mutations of
typical tumor suppressor genes were found spatially separated
over the tumor, illustrating convergent phenotypic evolution.
The study demonstrates the presence of branched evolutionary
tumor growth and Darwinian selection during tumorigenesis.
In addition to clonal evolution, reversible dedifferentiation
illustrates that individual cell clones can vividly adapt to their
surroundings in a struggle for survival. This adds a ‘‘clonal revo-
lution’’ perspective to the clonal evolution theory, in which
individual cancer cells can revolt to escape immune attack and
death.
A clear example of therapy-induced clonal evolution is the
acquired resistance of melanomas to Vemurafenib, a B-Raf
enzyme inhibitor. Vemurafenib is highly successful in eradicating
melanomas carrying the BRAF (V600E) mutation (Flaherty et al.,28 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.2010), which is found in roughly 60% of melanomas and 7% of
other cancers. Vemurafenib can achieve an impressive 80%
response rate in melanoma treatment. Nonetheless, recurrent
tumor cells employ either PDGFRb upregulation as an alternate
survival pathway or utilize mutated N-RAS as an alternate
MAPK activation route. Interestingly, the primary BRAF (V600E)
kinase target is not mutated in Vemurafenib-resistant clones
(Nazarian et al., 2010). Similar mechanisms account for the
clonal escape of other targeted therapies, such as Imatinib
(Gorre et al., 2001), or of conventional therapies, such as chemo-
therapy (Wang et al., 2004) or irradiation (Luzhna et al., 2013).
Tumor adaptation to microenvironmental changes such as
oxygen or nutrition deprivation occurs in a similar fashion by
selecting for the clones best fit to adapt to the new survival
conditions. As indicated by Gerlinger et al. (2012), these tumor
escapemechanisms are driven by the extreme genetic instability
and heterogeneity within tumors, which can be enhanced by
genotoxic treatments such as irradiation and chemotherapy.
Besides clonal evolution and clonal revolution, tumors
actively produce amicroenvironment that counteracts antitumor
immune responses. To accomplish immune suppression, tumor
cells employ various suppressive mechanisms, including the
expression of programmed cell death ligand 1 (PD-L1), the
production of indolamine 2,3-dioxygenase, or the induction of
T cell anergy (Gajewski, 2012). Alternatively, tumor cells can
attract other cell types that suppress invading immune cells
and support tumor growth and survival, such as tumor-infiltrating
macrophages, cancer-associated fibroblasts (Madar et al.,
2013), and, in particular, myeloid-derived suppressor cells
(MDSCs).
MDSCs are a heterogeneous population of immature myeloid
cells that originate from the bone marrow and normally differen-
tiate into macrophages, neutrophils, or dendritic cells (DCs).
During certain pathologies, including cancer, their natural differ-
entiation is halted, and they expand and infiltrate the tumor site
as MDSCs, attracted and activated by the local cytokine milieu
(Gabrilovich and Nagaraj, 2009; Heusinkveld and van der Burg,
2011). MDSCs induce a state of chronic tissue inflammation
and immune suppression (Bunt et al., 2006; Meyer et al., 2011)
that is characterized by the production of reactive oxygen spe-
cies (ROS), nitric oxide (NO), Arginase 1 (ARG-1), and cytokines
such as TNFa, IL-1, and IL-6 (Gabrilovich and Nagaraj, 2009).
They are forceful modulators of T and NK cell immunity, can
induce regulatory T (Treg) cells de novo in the periphery or attract
thymic-derived Treg cells (Fortin et al., 2012; Lindau et al., 2013),
and can give rise to suppressive tumor-associated macro-
phages (Gabrilovich and Nagaraj, 2009). For these reasons,
they will be in the focus of the following sections.
MDSCs rely strongly on the local NF-kB-driven inflammatory
milieu for their suppressive capabilities (Karin and Greten,
2005). At the early stages of tumor growth, NF-kB has a direct
impact on chronic inflammation-induced carcinogenesis (Greten
et al., 2004; Karin and Greten, 2005; Pikarsky et al., 2004), and a
vicious inflammatory circle exists between NF-kB activation
in MDSCs and subsequent NF-kB activation in malignant and
premalignant cells through the cytokines released from MDSCs,
as depicted in Figure 1. This ensures enduring NF-kB activation
in the malignant cells and continuous upregulation of antiapop-
totic and proliferative genes within the tumor, both of which
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Figure 1. Tumor Immune Suppression by MDSC Recruitment, Reciprocal NF-kB Signaling, and Reversible Dedifferentiation
Premalignant lesions can secrete cytokines such as IL-1 and IL-6 in order to attract myeloid-derived suppressor cells (MDSCs) from the bone marrow. Upon
infiltration of the tumor mass, MDSCs install a highly immunosuppressive environment, characterized by the production of reactive oxygen species (ROS), nitric
oxide (NO), and Arginase 1 (ARG-1), which are all potent repressors of T cell immunity. In turn, MDSCs also produce cytokines such as IL-1, IL-6, and TNF, which
activate NF-kB in local tumor cells. This stimulates the tumor cells to upregulate antiapoptotic and proliferative genes and incites them to producemore cytokines
such as TNF, IL-1, and IL-6. In turn, this again activates NF-kB inMSDCs, upregulating their cytokine production and augmenting their secretion of ROS, NO, and
ARG-1. Thereby, a vicious circle exists between tumor cells and MDSCs, which is based on reciprocal NF-kB activation through a cytokine secretion loop, firmly
maintaining a strong immunosuppressive tumor microenvironment. Importantly, by these cytokines, tumor cells can undergo reversible dedifferentiation, a
potent mechanism for escaping antigen-specific T cell recognition.
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inflammatory stimuli such as TNFa, IL-1b, IL-6, and IL-8 and
has also recently been linked to Wnt signaling and RelA-p65-
mediated dedifferentiation of intestinal epithelium cancer cells
(Schwitalla et al., 2013), illustrating that reversible tumor cell
dedifferentiation also depends on NF-kB. Indeed, a higher
infiltration of myeloid cells in the relapsed dedifferentiated
melanomas was also observed in comparison to primary differ-
entiated melanomas (Landsberg et al., 2010; 2012). Additionally,
hypoxic conditions in growing solid tumors activate HIF-1a,
which drives MDSCs to acquire a macrophage phenotype with
even broader T-cell-suppressive properties, thus affecting both
antigen-specific and -nonspecific T cell activity (Corzo et al.,
2010) predominantly via ROS, NO, and ARG-1 (Motz and Cou-
kos, 2013).
In order for cancer immunotherapy to make the leap toward
high efficacy, the tumor microenvironment first needs to be
made permissive and fully supportive of cytotoxic T and NK
cell immunity. To meet this challenge, approaches that escalate
the production of cytokines such as TNFa, IL-1, IL-6, and IL-8
within the tumor microenvironment need to be avoided. Recent
studies have shown that active intervention in the microenviron-
mental cytokine profile can revert MDSC suppression.
Local Innate Immune Sensing Shapes Tumor Immunity
Several recent studies provide evidence that breaking the
stronghold of MDSCs in the tumor microenvironment is a key
step toward effective antitumor immunity. For example, the
use of a monoclonal antibody against the IL-6 receptor elimi-
nates MDSC-mediated immunosuppression in mice (Sumida
et al., 2012) and ovarian cancer patients (Coward et al., 2011).Furthermore, cimetidine suppresses lung tumor growth in mice
through apoptosis induction in MDSCs (Zheng et al., 2013).
Notably IFNa and IL-12 have the capacity to convert MDSCs
into functional, nonsuppressive antigen-presenting cells. IL-12
reprograms MDSCs, forcing them to support CD8+ T cell attack
of solid tumors (Kerkar et al., 2011). Additionally, this IL-12-
induced reprogramming of MDSCs resulted in the upregulation
of costimulatory markers such as CD80, CD86, the differentia-
tion marker F4/80, and MHC-II as well as the inhibition of
ARG-1 and NO synthase 2 (Steding et al., 2011). IL-12 treatment
decreased in vivo MDSC infiltration of tumors and increased
CD8+ T cell infiltration and survival. The beneficial in vivo effects
of IL-12 on MDSC and tumor immunity were also seen in combi-
nation with chemotherapy, such as oxaliplatin (Hernandez-Alco-
ceba and Berraondo, 2012).
Like IL-12, the cytokine IFNa can potently induce MDSC
differentiation, promoting tumor immunity. IFNa used in vitro
or systemically in vivo stimulated the differentiation and matura-
tion of MDSCs within tumor tissue in the C26 colon carcinoma
model. Differentiated MDSCs displayed phenotypical changes
characteristic of maturation and exhibited a significantly reduced
T-cell-suppressive phenotype.
The systemic use of cytokines comes with drawbacks,
including toxicity and cost. In mice, IL-12- or IFNa-dependent
MDSC differentiation is also achieved with the TLR9 ligand
CpG (Zoglmeier et al., 2011). In the C26 colon carcinoma model
and in spontaneous gastric tumors in CEA424-Tag mice, CpG
administration induced MDSC maturation and differentiation
via the stimulation of TLR9 in plasmacytoid DC, resulting in
the reduced T-cell-suppressive activity of MDSCs and tumor
regression. In addition to intratumoral CpG administration,Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 29
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IFNa-neutralizing antibodies and type I IFN receptor-deficient
mice demonstrated that the strong MDSC-modifying effects of
CpG and polyI:C are dependent on type I IFN (Zoglmeier et al.,
2011). Similar results were obtained in large established CT26
colon carcinomas (Shirota et al., 2012). Although Zoglmeier
et al. (2011) did not find significant direct effects of CpG on
tumor-associated MDSCs, De Santo et al. (2008) reported a
screen of TLR agonists that did directly affect influenza-associ-
ated MDSC differentiation. In their work, the TLR7-8 ligand
R848, the TLR3 ligand polyI:C, and the TLR9 agonist CpG A-
type 2216 were all individually able to relieve the suppression
of T cells by isolated MDSCs. Importantly, the suppressive
capacity of MDSCs was further reduced when they were coincu-
bated with invariant NKT (iNKT) cells, thus maximizing IL-12
production. This interaction between MDSCs and iNKT cells
was CD1d and CD40 dependent. Direct exposure of MDSCs to
different IL-12- and/or IFNa-inducing TLR ligands or influenza
virus infection, particularly in the presence of iNKT cells, was
capable of inducing MDSC maturation and differentiation. In
line with these findings, the combinatorial use of CD40 activation
and polyI:C potently reverts the immune suppressive activity of
MDSCs and converts tumor-resident tolerogenic DCs into active
antigen-presenting cells. Upon anti-CD40 and polyI:C tumor
treatment without additional antigenic immunization, these cells
migrated from the tumor stroma to local lymph nodes, activated
significant T cell immunity, and induced the rejection of other-
wise lethal intraperitoneal ID8 ovarian carcinomas. Again, IL-12
and IFNa were the predominant cytokines mediating these ef-
fects (Scarlett et al., 2009). Besides individual cytokines and
TLR ligands, an oncolytic adenovirus engineered for increased
TLR9 stimulation has recently achieved similar TLR9-dependent,
MDSC-modulating, and T-cell-immunity-stimulating results in a
xenograft model of lung cancer and a syngeneic melanoma
model (Cerullo et al., 2012). Furthermore, anti-CD40 treatment
combined with gemcitabine, a chemical nucleoside analog that
is incorporated in proliferating tumor cells alternative to cytidine,
thereby arresting tumor growth, was reported to induce tumor
regression upon MDSC reprogramming in a small cohort of
pancreatic cancer patients (Beatty et al., 2011).
The studies above clearly demonstrate that immune modula-
tors such as the TLR ligands CpG, R848, and polyI:C as well
as the cytokines IL-12 and IFNa are capable of converting the
IL-1-, IL-6-, and TNFa-dominated immunosuppressive tumor
microenvironment into a T-cell-immunity-promoting tissue.
Notably, such tumor microenvironmental conversions attract
T cells to the tumor tissue. Inevitably, activated T cells release
TNFa in the tumor microenvironment, and, in principle, this
may tip the balance back toward MDSC formation and tumor
cell dedifferentiation. However, the studies above and their prac-
tical outcomes demonstrate that microenvironmental changes
are maintained in favor of antitumor immunity. Nonetheless,
more scrutiny into the exact kinetics and temporal stability of
MDSC conversion is warranted.
Importantly, by the use of TLR ligands, MDSC conversion still
predominantly depends on the recruitment and ample presence
of (plasmacytoid) DCs at the tumor site. TLR ligands usually
have no direct effects on tumor cells, and, consequently, the
efficacy of such interventions heavily depends on the ability of30 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.the immune system to localize functional antigen-presenting
cells to the tumor tissue (Palucka and Banchereau, 2013).
Moreover, most solid tumors are poorly vascularized and
contain areas of hypoxia. Besides attracting MDSCs (Murdoch
et al., 2004), poor tumor vascularization limits the access of
systemically administered cytokines (such as IL-12 or IFNa) or
antibodies (such as CD40-agonistic mAb or anti-IL-6 mAb).
Therefore, the efficacy of such interventions is limited by the
local access to and availability of the target cell population.
Novel Compounds Targeting Immune Receptors
Expressed in Tumor Cells
The innate cytosolic immune sensor RIG-I is structurally related
to MDA5, and both belong to the RIG-I-like receptor (RLR) family
of helicases that recognize double-stranded RNA (dsRNA) upon
the viral infection of their host cell. Importantly, RLRs reside in all
nucleated cells in the body, including tumor cells. Although
MDA5 recognizes long dsRNA structures, such as those found
in polyI:C, the hallmark activating structure for RIG-I has been
defined as short, blunt-ended 50-triphosphate dsRNA (3pRNA)
(Hornung et al., 2006; Pichlmair et al., 2006; Schlee et al., 2009).
In addition to type I IFN induction in immune, nonimmune, and
tumor cells, tumor cells are highly susceptible to RIG-I-induced
apoptosis via the activation of the BH3-only proteins Puma
and Noxa. Importantly, nonmalignant cells are rescued from
RIG-I-induced apoptosis by their ability to upregulate Bcl-xL
(Besch et al., 2009). Thus, unlike TLR ligands, 3pRNA is a direct
tumoricidal agent. When used in vivo against melanoma, 3pRNA
induces high amounts of IFNa, IFNb, and IL-12 and mediates
effective antitumor immunity in melanoma and other cancer
types (Poeck et al., 2008). RIG-I activation can be combined
with gene silencing, and such so-called bifunctional small inter-
fering RNAs (siRNAs) (for example, RIG-I activation combined
with Bcl2 silencing) have shown efficacy in a melanoma lung
metastasis model (Poeck et al., 2008). Another successful
bifunctional siRNA is RIG-I triggering combined with the
silencing of TGF-b in pancreatic cancer in mice, which leads to
the recruitment of CD8+ T cells to the tumor site along with a
reduction of MDSC tumor infiltration (Ellermeier et al., 2013).
3pRNA is either generated by in vitro transcription or chemically
synthesized. Such RNAs usually trigger TLR7 in DCs, a process
which has a deteriorating effect on the RIG-I-induced IFN
response (Forsbach et al., 2012). With the discovery of the exact
minimal RIG-I ligand (Schlee et al., 2009) and the specific inter-
action between 3pRNA and RIG-I (Wang et al., 2010), RIG-I-
selective RNA agonists can be designed with optimized charac-
teristics for cancer immunotherapy. Collectively, RIG-I triggering
in tumor cells has the unique property of exhibiting selective tu-
moricidal activity in addition to strong type I IFN induction in both
3pRNA-stimulated tumor cells and immune cells.
In addition to its strong IFN signature, RIG-I in myeloid cells
activates the inflammasome via the direct association of RIG-I
and the ASC adaptor protein (Poeck et al., 2010). For RIG-I,
inflammasome signaling is independent of NLRP3 (Kanneganti
et al., 2006; Poeck et al., 2010; Rajan et al., 2010). Although
NLRP3-dependent inflammasome activation in MDSCs leads
to the release of IL-1b, promoting immune suppression by
MDSCs (Bruchard et al., 2013), in the case of RIG-I, type I IFN
blunts the caspase-1-mediated production of IL-1b. IFNs induce
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Figure 2. Reversal of the Tumor Immunosuppressive Environment by RIG-I-Induced Type I IFN Production and MDSC Conversion
Established tumors often carry an immunosuppressive microenvironment dominated by MDSCs that effectively inhibits T cell attack. This MDSC-dependent
immune suppression can be reverted, for example, by injecting the RIG-I ligand 50-triphosphate RNA (3pRNA) complexed to in vivo transfecting agents such as
polyethylenimine, directly into the tumor mass. Upon entering MDSCs, 3pRNA will trigger the cytoplasmic innate immune sensor RIG-I and induce strong type I
IFN production by these cells. Moreover, upon entering tumor cells, 3pRNA will trigger their RIG-I sensor too, importantly leading to tumor cell apoptosis and the
release of tumor-associated antigens. The IFNa produced by MDSCs will cause their differentiation into effective antigen-presenting cells and effectively
terminate the cytokine-dependent reciprocal NF-kB signaling loop between tumor cells and MDSCs. The MDSC-derived, locally differentiated antigen-
presenting cells are capable of taking up the tumor-associated antigens released by the dying tumor cells and can travel to the local lymph node in order to
induce effective T cell activation against these antigens. In response, these T cells can nowmigrate to the tumor site, which will now support strong T cell effector
function by its IFNa-dominated immunosupportive microenvironment. On site, these tumor-responsive T cells can engage in effective tumor cell attack, liberated
from MDSC-mediated tumor immune suppression.
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signaling and the reduction of pro-IL-1b amounts by an addi-
tional IL-10-STAT3-dependent autocrine loop (Guarda et al.,
2011).
Oligonucleotides such as 3pRNA can be easily injected intra-
tumorally when complexed with in vivo transfection agents such
as polyethylenimine. The presence of 3pRNA in tumor tissue
provides a highly immunogenic tumor microenvironment in
which abundant tumor antigens are released upon RIG-I-
induced tumor cell death, processes collectively depicted in
Figure 2. Notably, intratumoral injections of tumor lesions before
surgical excision can make transient use of tumor tissue as a
source of tumor antigen.
Optimizing Therapeutic Tumor Vaccination
Although the conversion of the tumor microenvironment into an
immune-fostering state is a pivotal step toward the induction
of protective tumor immunity, the simultaneous administration
of a more conventional cancer vaccine distant from the tumor
site can broaden and peak the specific activation of antitumor
T cell populations. CD4+ and CD8+ T cells induced by such a
vaccine complement T cell activity induced by changes in the
tumor microenvironment. A simultaneous vaccination distant
from the tumor site is particularly important, given that it allows
for the coordination of CD4+ T cell help for the CD8+ T cell frac-
tion. Tumor antigen-specific CD4+ T cells augment the clonal
expansion of tumor-specific CD8+ T cells (Wong et al., 2008).
Moreover, tumor antigen-specific CD4+ T cells in the tumor
microenvironment facilitate tumor infiltration by tumor-specificCD8+ T cells, augmenting their local proliferation, survival, and
tumoricidal effector function. Thus, CD4+ T cell help amplifies
the CD8+ T cell response in both initiation and the effector phase
(Bos and Sherman, 2010; Wong et al., 2008).
Several tactics exist for orchestrating combined CD4+ and
CD8+ T cell immunity. Although live vaccines are considered
to be the most potent forms of immunization because of their
limited replicative potential and seamless colocalization of
antigens and multiple PAMPs, TLR ligand-protein conjugates
exert a stimulating synergy that comes close to that of a live
vaccine (Heit et al., 2005). Although containing the whole array
of suitable epitopes for (cross-)presentation, protein antigens
are difficult to generate, especially on a good manufacturing
practice (GMP) level, given that protein production often involves
bacterial synthesis, which is inevitably prone to endotoxin
contamination. Therefore, synthetic peptides such as synthetic
long peptides (SLPs) can be used for vaccination purposes
because they mimic the antigenic properties of a whole protein
antigen; i.e., they contain an array of antigens for both helper
CD4+ and cytotoxic CD8+ T cell responses irrespective of the
patient’s human leukocyte antigen (HLA) type, allow direct anti-
gen presentation by professional antigen-presenting cells (Bijker
et al., 2008), and were shown to induce strong, effective CD8+
T cell responses (Quakkelaar and Melief, 2012). In clinical trials,
SLP vaccines in montanide ISA-51 adjuvant have been excep-
tionally effective (for an overview of vaccine adjuvants, see Table
1). An HPV16-SLP vaccine for patients with high-grade vulvar
intraepithelial neoplasia has shown strong T cell immunity and
impressive clinical responses (Kenter et al., 2009). Additionally,Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 31
Table 1. Characteristics of Several Different Immune Adjuvants
Receptor
Immune
Skewing
Main Target
Cell
Non-Tumor-Targeting Adjuvants in Clinical Trialsa
Alum nonspecific Th2 APC
Ampligen TLR3 Th1 APC
AS03 nonspecific Th2 APC
CpG 7909 TLR9 Th1, Th2 APC
Imiquimod TLR7,8 Th1 APC
Iscomatrix nonspecific Th1, Th2 APC
MDP NOD2, NLRP3 Th1 APC
MF59 nonspecific Th1, Th2 APC
Montanide ISA 51 nonspecific Th1 APC
MPL nonspecific Th1, Th2 APC
PolyICLC TLR3 Th1 APC
VTX-2337 TLR8 Th1 APC
Experimental Tumor-Targeting Adjuvants
3pRNA
(in vivo transfected)
RIG-I, TLR7 Th1 tumor, APC
polyIC
(in vivo transfected)
MDA5, TLR3,7 Th1 tumor, APC
aSource: National Cancer Institute.
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responses in different trials of ovarian cancer patients (Leffers
et al., 2009; 2012) as well as colorectal cancer patients (Zees-
traten et al., 2013). Interestingly, these SLP vaccines perform
well in combination with classical therapies such as chemo-
therapy (Vermeij et al., 2012), and, in particular, the addition of
IFNa results in the augmentation of the induced T cell response
(Zeestraten et al., 2013). Notably, IFNa also improves cross-
presentation by DCs (Lattanzi et al., 2011).
Although SLP vaccines are effective in inducing immunity and
are capable of mediating therapeutic immunotherapy against
virus-associated cancer (Kenter et al., 2009), responses to
self-antigens such as p53 have shown strong immune activation
but have done so without significant beneficial clinical outcome.
As recently reviewed by Zom et al. (2012), a means for further
potentiating SLP vaccines can be the conjugation of such pep-
tides directly to TLR ligands. These conjugates are able to deliver
SLP antigens to DCs and simultaneously couple these antigens
to direct TLR activation for the induction of superior antitumor
immunity. TLR ligand-peptide conjugates have been tested
in vitro and in vivo with either CpG or Pam3CysSK4. Such conju-
gates ensure enhanced peptide uptake and processing and
significantly intensify the resulting T cell response in comparison
to experiments performed with uncoupled TLR ligands and
peptides (Khan et al., 2007). In general, it appears that linking
an antigen to a targeting moiety improves DC cross-presenta-
tion. This is also demonstrated by DCs exposed to antigen-
antibody immune complexes (Schuurhuis et al., 2002). Both
immune complexes and the TLR ligand-peptide conjugates
deliver antigens to antigen storage compartments within DCs,
which enable DCs to engage in prolonged CD8+ T cell cross-
priming (van Montfoort et al., 2009; Zom et al., 2012).32 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.Besides linking an antigen to a TLR ligand to enhance uptake
and processing, DCs provide an array of receptors specialized
in the uptake of specific antigenic matter. For example, CD8a+
DCs can potently cross-present antigens from necrotic cells,
such as virally infected cells or dying tumor cells, using the
C-type lectin domain family member 9a (CLEC9a or DNGR1)
(Sancho et al., 2009). Although CLEC9a favors the cross-presen-
tation of antigens in viral infection (Iborra et al., 2012; Zelenay
et al., 2012), the uptake of antigens via CLEC9a allows for the
tuning of the resulting antigen presentation, depending on the
modulation of the induced CD4+ T cell response. The coupling
of antigens to CLEC9a-specific antibodies without the addition
of adjuvants mainly induces Foxp3+ CD4+ Treg, whereas, in
the same immunization, the addition of polyI:C resulted in strong
cross-presentation and IL-12-dependent induction of CD8+
T cell immunity. In contrast, curdlan adjuvants induced a Th17-
cell-focused response (Joffre et al., 2010). Additional antigen up-
take receptors exist that can be effectively exploited for
enhancing antigen cross-presentation, including CLEC7a (Dec-
tin-1), DC-SIGN (CD209), DEC205 (CD205), and the mannose-
1 receptor (CD206). Moreover, other cell types, such as NK
and NKT cells, can influence DC cross-presenting capabilities.
NK cells can inhibit cross-priming in a TRAIL-DR5-dependent
manner (Iyori et al., 2011), which is counteracted by inhibiting
this interaction between NK cells and DCs, for example, by
locally administered antibodies against DR5. In contrast, NKT
cells can enhance cross-priming in a CD1d-dependent manner,
which can be exploited for enhancing cross-priming by adding
a-galactosylceramide as a CD1d adjuvant to the immunization
(Semmling et al., 2010).
Effective CD8+ T cell priming also requires a cytokine environ-
ment that is dominated by type I IFN and IL-12, which act as a
third costimulatory signal. These cytokines have been shown
to be crucial for the activation of naive T cells (Curtsinger et al.,
1999) and CD8+ memory T cells (Raue´ et al., 2013) and sustain-
ing effective antitumor CD8+ T cell immunity (Schurich et al.,
2013; Steding et al., 2011). IFNa and IL-12 program the activated
T cells to become effective memory cells (Xiao et al., 2009). They
upregulate a set of approximately 350 genes through epigenetic
changes that program CD8+ T cell effector function and memory
development (Agarwal et al., 2009). To prevent bystander
activation of naive CD8+ T cells in an IL-12 or IFNa cytokine
milieu, the process is under the control of CD4+ T cell help and
is dependent on a paracrine IL-2 loop (Raue´ et al., 2013).
Importantly, an effector environment dominated by IFNa and
IL-12 induces antigen-independent activation and proliferation
of CD8+ memory T cells prior to the recognition of their cognate
antigen (Raue´ et al., 2013; 2004). According to the model
proposed by Raue´ et al. (2013), this phenomenon allows
memory CD8+ T cells to initiate differentiation and effector
functions upon entering the periphery of an infection site and
its inflammatory microenvironment, enhancing the host’s
response to the microbial invasion by ‘‘preheating’’ the T cell
for action. In the case of tumors, not only do compounds
such as the RIG-I agonist 3pRNA revert MDSC immune
suppression, induce tumor cell apoptosis, and liberate tumor-
associated antigens for immunity, but memory CD8+ T cells
residing in or near the tumor site are simultaneously enticed
in order to activate their IL-12-IFN-programmed effector
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Reviewfunctions. Moreover, the CD8+ T cells that are newly raised
against the liberated tumor antigens will encounter a tumor
cytokine environment that is fully supportive for effector func-
tions and memory development.
Thus, peptide vaccines can set the stage for strong T cell
activation simultaneous with 3pRNA tumor treatment. T cells
induced by such vaccines are enabled to exert and sustain
their cytotoxic antitumor functions within a tumor microenviron-
ment that is liberated from MDSC suppression through intratu-
moral 3pRNA treatment. However, the induction and effector
functions of these T cells are still restrained by natural regulatory
mechanisms.
Releasing Natural Inhibition by Checkpoint Blockade
T cell numbers that engage in tumor attack can be maximized
in two different phases: during T cell priming and during recogni-
tion of the target cell. The priming phase of a T cell response
involves three stimulatory signals: MHC:TCR interaction, CD80
and CD86:CD28 costimulation, and the cytokine milieu. As one
of the natural limitations to T cell proliferation, primed T cells up-
regulate CTLA4 upon cognate antigen recognition, which com-
petes with CD28 for interaction with the costimulatory molecules
and effectively shuts down the priming phase. In addition to this
brake on T cell activation, activated DCs and tumor cells express
ligands such as PD-L1 (also known as CD274 or B7-H1). PD-L1
interacts with PD1 expressed on activated T cells. When PD1 is
engaged by PD-L1, it inhibits TCR-driven proliferation and cyto-
kine production (Freeman et al., 2000) and also severely shortens
TCR:MHC interactions (Fife et al., 2009). Thereby, interactions
such as PD1-PD-L1 have a deteriorating effect on T cell priming
and target cell recognition and killing. Indeed, the active inhibi-
tion of CTLA4 (Leach et al., 1996) or PD1interactions (Nishimura
et al., 1999) produces exaggerated immune responses. Besides
CTLA4 and PD1, a collection of additional checkpoints and re-
ceptors exist, and a comprehensive review on the subject is pub-
lished in this issue of Immunity (Chen and Mellman, 2013).
In the clinical setting, CTLA4 blockade by Ipilimumab was
approved by the FDA for the treatment of metastatic melanoma
in 2010. Ipilimumab has achieved significant immunological as
well as clinical responses, nearly doubling the median overall
survival time irrespective of an additional gp100 peptide vacci-
nation, in patients with unresectable late-stage melanoma
(Hodi et al., 2010). As expected, grade 3 or 4 adverse autoim-
mune side effects accompany Ipilimumab treatment, and they
appear to coincide with its antitumor effect. Adverse effects
could be reversed by appropriate treatment. Also, in patients
with previously untreated metastatic melanoma, Ipilimumab
acts in combination with the standard-of-care chemotherapeutic
agent dacarbazine (Robert et al., 2011). Likewise, Ipilimumab
significantly increased progression-free survival in combination
with paclitaxel and carboplatin used in non-small-cell lung can-
cer (NSCLC) (Lynch et al., 2012) and, as a single agent, shows
efficacy in renal cancer treatment (Yang et al., 2007). Clearly,
the inhibition of the CTLA4 immune checkpoint is a fruitful inter-
vention for boosting antitumor immunity.
For the PD1 pathway, first reports indicated that anti-PD1
treatment induces durable objective responses as a single agent
in one out of four to five patients with melanoma, renal cancer,
or NSCLC (Topalian et al., 2012). In patients with advanced-stage cancer, anti-PD1 treatment induced durable regressions
(Brahmer et al., 2012), and Lambolizumab (the antibody against
PD1 previously known as MK-3475) treatment of advanced mel-
anoma recently achieved response rates up to 52% with low-
grade adverse effects (Hamid et al., 2013). Treatment outcome
appears to correlate with tumor-associated PD1 expression (To-
palian et al., 2012), and adverse immune side effects seen with
anti-PD1 treatment appear to be less common and less severe
than those seen following Ipilimumab treatments (Brahmer
et al., 2012).
With effective checkpoint blockade, augmented therapeutic
vaccination, and tumor microenvironmental conversion, we
now have a broad range of tools at hand that spans the immune
response from its priming to its effector phase. New combinato-
rial immunoregimens can be shaped, such as deploying RLR and
TLR immunostimulatory agents to augment different phases of
the antitumor immune response. Hereby, checkpoint inhibition
permits the T cell response to be released from its natural brakes
and be propelled in order to exert its full force.
Advanced Clinical Protocols for Tumor Immunotherapy
The majority of the interventions discussed above are indepen-
dent of patient HLA haplotype, can be made in large quantities
on a GMP level, and can be combined with other therapies.
Also, conventional anticancer regimens such as chemotherapy
and irradiation can be incorporated in such therapeutic combi-
nations. It is well known that certain types of chemotherapy,
for example anthracyclines, can induce immunogenic cancer
cell death. This occurs predominantly via the exposure of calre-
ticulin, acting as a phagocyte ‘‘eat me’’ signal, and the release of
HMGB1 (Orsini et al., 1977; Zitvogel et al., 2008). Moreover, local
irradiation of a tumor mass sometimes leads to the regression of
metastases distant from the radiation field, a phenomenon
referred to as the abscopal effect (Demaria and Formenti,
2012). Rarely sufficient to induce systemic cancer regression,
the abscopal effect probably represents a systemic immune
response triggered by the irradiation of tumor cells. Indeed, the
abscopal effect appears to coincide with systemic immune acti-
vation (Postow et al., 2012), which could be initiated by the irra-
diation-induced modulation of the tumor peptide repertoire and
MHC class-I expression (Reits et al., 2006).
Besides these conventional approaches, targeted therapies,
such as vemurafenib (Flaherty et al., 2010) in melanoma and tas-
quinimod (Pili et al., 2011) in prostate cancer, can lead to partial
tumor regression, providing a time window for immunological
intervention such as adoptive transfer therapies like sipuleucel-T
(Kantoff et al., 2010), adoptive T cell transfer therapy (Restifo
et al., 2012), or therapeutic vaccination (Kenter et al., 2009).
Depicted in Figure 3, an immunotherapeutic intervention should
influence all levels of the immune response simultaneously,
attending its entirety. As an essential step accompanying any
tumor immunotherapy regimen, the tumor microenvironment
has tobeconverted froman immunosuppressivestroma intoa tis-
suemilieu in ruthless supportofCD8+Tcell infiltrationandeffector
function. Key cytokines to this reversal are type I IFN and IL-12.
Targeting innate nucleic acid sensors expressed in tumor cells,
such as RIG-I, allows such a switch in the tumor microenviron-
ment, given that tumor cells themselves start to make type I
IFN, release tumor-specific antigens, and undergo cell death.Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 33
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MDSC reprogramming of the tumor microenvi-
ronment should be undertaken in order to liberate
the tumor tissue from its immunosuppressive
environment, converting MDSCs to effective
antigen-presenting cells and facilitating the T-cell-
mediated attack of the tumor cells.
Such MDSC reprogramming should be accom-
panied by a vaccination optimized to induce
maximum CD8+ T cell immunity. A large panel of
antigens covering CD4+ helper T cell and CD8+
cytotoxic T-cell-specific epitopes should be em-
ployed in the form of overlapping synthetic long
peptides (SLPs). Coupling these SLPs directly to
a Toll-like receptor (TLR) ligand augments den-
dritic cell (DC) activation and subsequent antigen
presentation. Moreover, such TLR ligand-peptide
conjugates ensure the formation of an antigen
depot within the responding DCs, prolonging
DC antigen cross-presentation to CD8+ T cells.
Choosing a TLR ligand such as CpG will ensure
IL-12 and IFNa production by the activated DCs,
augmenting T cell priming and effector function.
Additionally, adjuvants such as a-galactosylcer-
amide may be included in the vaccination to exploit NKT-cell-mediated stimulation of DC antigen cross-presentation.
The activation and effector phase of the T cell response itself needs to be amplified by releasing the T cell response from its natural regulatory inhibitions. By
using systemic antibody-mediated CTLA4 or PD-1 blockade, physiological immune checkpoints to limit T cell proliferation upon activation or T cell effector
function upon target cell recognition, respectively, are blocked.
The 3pRNA-mediated MDSC reprogramming and reversal of the tumor’s immunosuppressive environment will ensure that high levels of IFN-a will be produced
locally. T cells proliferate in the IL-12 and IFNa inflammatory environment, and tumor cell killing can initiate upon target cell recognition. This shortens T cell
effector function response time. Intervening in the immune response as a whole, instead of influencing only a subsection of its response, brings the goal of
effective cancer immunotherapy within reach.
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ReviewSimultaneous therapeutic vaccination protocols should
contain a broad spectrum of tumor antigens, which is needed
for the synchronized induction of ample CD4+ helper T cell and
CD8+ cytotoxic T cell immunity and preferably contains antigens
that span different antigenic subclasses in order to counteract
reversible tumor cell dedifferentiation. Such broad antigen
panels can be incorporated into overlapping SLP vaccines.
Then, to enhance the vaccine-induced generation of T cell
immunity, the SLPs can be conjugated to TLR ligands that
strongly induce IFNa and IL-12 secretion by the responsive
DCs, such as CpG. This augments CD8+ T cell activation and
effector function and allows for programmed proliferation of
these cells upon reaching the RIG-I-converted tumor environ-
ment dominated by IFNs. Furthermore, including additional
adjuvants such as a-galactosylceramide in the vaccination can
exploit NKT-cell-mediated stimulation of such antigen cross-
presentation. Finally, the T cell response should be released
from its natural inhibitions by blocking CTLA4 or PD1, thus
allowing maximized T cell effector function.
The bottleneck of such combinatorial immune interventions
in cancer is its immunosuppressive shield. The great advance
we are now witnessing is that, by targeting the heart of the
tumor cell’s own antiviral defense system (i.e., RIG-I), this shield
can not only be broken, but the entire tumor can be turned into
a vaccine. Once this is achieved, all other immunotherapeutic
regimens synergize to further strengthen the resulting antitumor
response. In combination with classical therapies such as
irradiation or chemotherapy or as a stand-alone regimen, we
are likely to see such combinatorial immunotherapeutic strate-
gies enter the clinical routine in the future.34 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.REFERENCES
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